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Not surprisingly, low-income, uninsured people report more problems obtain-
ing prescription drugs because of costs 
than people with insurance.  For example, 
26 percent of uninsured adults in 2003 
did not purchase at least one prescription 
drug because of cost, compared with 8.7 
percent of people with employer coverage.1 
Moreover, prescription drug prices and utili-
zation have continued to rise.2 
Yet low-income, uninsured people 
generally lack access to state and federal 
pharmaceutical assistance programs and 
often cannot afford to fill prescriptions 
at retail pharmacies. While a number of 
states have prescription drug assistance 
programs, they have been targeted primar-
ily toward Medicare beneficiaries. Although 
the federal government started providing 
prescription drug coverage for Medicare 
beneficiaries in 2006, many states with drug 
assistance programs have provided ongoing 
support to seniors by, for example, supple-
menting their cost-sharing requirements. 
And in early 2006 many states stepped in 
to cover prescription drugs temporarily 
for dually eligible Medicare and Medicaid 
beneficiaries when problems arose with 
Medicare coverage.  
Communities play a key role in provid-
ing prescription drugs for low-income, 
uninsured people, who often seek medica-
tions from the same safety net providers 
who offer medical services and prescribe 
the medications, according to HSC’s 2005 
site visits to 12 nationally representative 
(see Data Source). Safety net hospitals and 
community health centers (CHCs) typically 
have on-site pharmacies or contract with 
outside pharmacies to offer a full range of 
medications, usually charging patients a 
copayment. Free clinics and other small 
providers often can dispense only limited 
quantities or types of medications. To help 
control drug costs, safety net providers fre-
quently use generic drugs, and some have 
adopted preferred drug lists.  As the num-
ber of uninsured Americans rises, commu-
nity safety net providers are treating more 
uninsured patients without proportionate 
funding increases.  
Safety Net Rx Strategies 
To help subsidize and reduce the cost of 
prescription drugs for low-income, unin-
sured people, safety net providers—in some 
cases in collaboration with community-
level programs—have built on existing 
strategies and developed new ones. Many 
CHCs and safety net hospitals have access 
to a federal prescription drug discount 
program. And while all types of safety net 
providers have long dispensed manufac-
turer drug samples to patients, they have 
developed more structured ways of obtain-
ing ongoing supplies of the most commonly 
prescribed medications. These strategies 
include—in general order of promi-
nence—increased use of federal discounts; 
obtaining donated prescription drugs from 
manufacturers; use of public and private 
While the new Medicare drug benefit has helped alleviate concerns about prescription 
drug access for elderly and disabled Americans, many low-income, uninsured people 
under age 65 continue to rely on community safety nets to get needed medications.  As 
the number of uninsured Americans increases, safety net providers are stretching limited 
resources to meet growing prescription drug needs, according to findings from the Center 
for Studying Health System Change’s (HSC) 2005 site visits to 12 nationally representa-
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and donated medications—to make affordable drugs available to needy patients, safety 
net providers and community advocates report that many low-income, uninsured people 
continue to face major barriers to obtaining prescription drugs. 
THE COMMUNITY 





By Laurie E. Felland, Erin Fries Taylor 
and Anneliese M. Gerland
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funding to subsidize drugs; and establish-
ing discounts for uninsured people at local 
retail pharmacies. 
340B Discounts
Since 1992, community health centers 
that are federally qualified (FQHCs) and 
safety net hospitals receiving federal dis-
proportionate share hospital (DSH) pay-
ments have been eligible for discounts on 
brand name and generic prescription drugs 
through the federal 340B Drug Pricing 
Program, which requires pharmaceutical 
manufacturers to give eligible providers 
discounts equal to or greater than those 
received by Medicaid.3 Providers distribute 
these drugs to patients through their own 
pharmacies or through contracted retail 
pharmacies, charging patients a sliding-
scale fee based on income. A 2004 study 
estimated that the 340B discounts saved 
providers participating in the program at 
least 27 percent of annual outpatient drug 
expenditures.4
Use of the 340B program has grown 
in recent years.5 While all of the 12 HSC 
communities have at least one safety net 
provider participating in the 340B pro-
gram, some communities—including 
Boston, Cleveland, Indianapolis, Miami 
and Seattle—have a broad network of 
participating hospitals and health centers. 
And more safety net providers across the 
communities recently have applied for 
the program. Furthermore, recent federal 
legislation expanded 340B pricing to out-
patient drugs at certain children’s hospitals, 
although these hospitals may have difficul-
ties meeting DSH requirements.6 
Manufacturer Assistance Programs
Many safety net providers—including those 
that participate in 340B—rely on pharma-
ceutical manufacturer assistance programs 
to obtain free or reduced-cost prescription 
drugs for patients. As a group, manufactur-
ers have significantly increased the amount 
of drugs donated through these programs, 
with the number of free prescription medi-
cines distributed growing from approxi-
mately 3 million in 1998 to 22 million in 
2004, according to the Pharmaceutical 
Research and Manufacturers of America 
(PhRMA), an industry trade group. 
Manufacturer assistance programs vary 
but are typically available to uninsured 
people, generally with household incomes 
below 200 percent of the federal poverty 
level, or $40,000 for a family of four in 
2006. Applicants also must demonstrate 
citizenship or legal immigrant status. 
However, eligibility requirements, including 
age and income restrictions, vary, and some 
programs do not publicly disclose their 
requirements. Application processes also 
differ by drug company and/or by program, 
and many companies run multiple pro-
grams to cover different medications. 
To help people navigate the varied eli-
gibility criteria and application processes 
for the multiple programs, some states 
and not-for-profit groups have worked 
with drug manufacturers to establish Web 
sites, such as www.Rx4NJ.org and www.
needymeds.com, and PhRMA has a Web 
site called the Partnership for Prescription 
Assistance at www.pparx.org. While market 
observers indicate these Web sites are help-
ful, the sites do not offer a single standard-
ized application for multiple companies’ 
programs. In addition, applicants’ health 
care providers (physicians and other staff) 
need to be involved in authorizing the 
requests and dispensing the medications. 
Given the complexity of the application 
process, many safety net providers help 
uninsured patients apply for manufac-
turer assistance programs. In recent years, 
providers increasingly have tapped into 
manufacturer assistance programs through 
a number of approaches:
• Many providers have hired staff and 
devoted other resources to bring in 
more donated prescription drugs. A 
health center in Lansing, for example, 
found that dedicating one full-time staff 
member to this effort generated more 
than $300,000 worth of free medica-
tions in one year. In Cleveland, the 
county hospital now assists physicians 
in obtaining donated drugs for their 
patients through automated prompts in 
the hospital’s electronic medical record 
system. 
• Some safety net hospitals and CHCs 
have arranged for bulk replacement, 
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a process where drug manufactur-
ers stock providers’ pharmacies with 
medications that providers dispense to 
patients determined to be eligible for 
the manufacturer’s assistance program 
but who have not applied individually. 
This practice allows the pharmacy to 
offer these medications immediately 
to patients, rather than pursuing each 
individual application. The county hos-
pital in Indianapolis acquired more than 
$3 million worth of free drugs through 
bulk replacement last year, double the 
level from two years earlier.
• Some community programs that rely on 
private physicians donating medical care 
to uninsured patients also help patients 
obtain prescription drugs from manu-
facturers. Such donated-care programs, 
in which participating physicians agree 
to provide a certain amount of free 
medical care each year, are administered 
through local medical societies or other 
community organizations and often 
help link enrollees to manufacturer pre-
scription drug assistance programs. In 
fact, the need for prescription drugs is 
reportedly the main benefit people seek 
when applying to the program in Little 
Rock. Plus, including prescription drugs 
is important to physician participation 
in donated-care programs because of 
concerns about treating patients who 
cannot afford to fill prescriptions.
Given the implementation of the 
Medicare drug benefit, pharmaceutical 
manufacturers are now re-examining their 
drug assistance programs. To the extent 
that manufacturers focus less on Medicare 
beneficiaries in the future, there may be an 
opportunity to offer donated drugs to addi-
tional low-income, uninsured people.  
Safety Net Programs to Coordinate Care
Another way a few communities fund pre-
scription drugs for low-income, uninsured 
people is through programs that provide 
primary and preventive care through safety 
net providers, coordinate access to spe-
cialty care and encourage appropriate use 
of other services, such as emergency care.  
Prescription drugs are included as a vital 
part of managing patients’ conditions. In 
addition to tapping into available 340B dis-
counts through participating hospitals and 
health centers, these programs use a por-
tion of their funding from federal and state 
DSH payments, state charity care pools or 
local property taxes to offer medications to 
enrollees, usually for a small copayment. 
Such programs in Lansing, Indianapolis 
and Boston offer prescription drugs to a 
large and growing number of people. For 
example, the Health Advantage program 
in Indianapolis now serves about 50,000 
people—half of the county’s uninsured 
population.
Private Funding and Discount Cards
Some safety net providers have pursued 
funding from private, usually local, philan-
thropies to subsidize drug costs. While free 
clinics are particularly reliant on private 
funding, some CHCs and hospitals also 
have turned to foundations for assistance 
when existing programs and funding could 
not fulfill the need. 
In a few communities, local drug card 
programs have been initiated recently that 
allow residents to purchase discounted 
prescription drugs from retail pharmacies. 
Local governments in Lansing and north-
ern New Jersey, for example, have negoti-
ated discounts with retail pharmacies. Such 
discounts vary considerably across pro-
grams and medications. In some cases, dis-
count cards are part of a broader medical 
discount program. For instance, the new 
HealthCare Connect program in Phoenix 
provides discounts on medical services and 
prescription drugs.
Impact of Rx Strategies
In general, individual safety net providers 
and programs report that pursuing these 
strategies has helped keep low-cost medica-
tions available to their low-income, unin-
sured patients. Yet the ability and capacity 
to use the range of strategies varies across 
providers, and several inherent limitations 
remain for both safety net providers and 
their patients. 
• Provider costs:  Although the 340B 
program allows many safety net provid-
ers to purchase prescription drugs at 
a discount, these providers still must 
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subsidize drug costs for patients. And 
while many safety net providers and 
communities have streamlined how 
they participate in manufacturer assis-
tance programs, the time and resources 
required to tap into these programs 
is prohibitive for small providers and 
free clinics with more limited budgets. 
Moreover, many safety net providers 
feel increasingly strapped for resources 
as they try to cope with a rising num-
ber of uninsured patients and they find 
it harder to keep pace with the rising 
cost of drugs, even when significant 
discounts are available.  
• Patient costs: Although generally a 
small percentage of the total medica-
tion cost, the copayments or other cost 
sharing required by safety net provid-
ers and prescription programs can pose 
barriers for low-income people, and 
some providers have increased their 
pharmacy copayments over the last few 
years.  Plus, recent discount-card initia-
tives typically require significant out-
of-pocket spending. Although provid-
ers often offer a short-term supply of 
medication to patients unable to con-
tribute to the cost, such patients may 
struggle to comply with a longer-term 
drug regimen. Manufacturer assistance 
programs can help fill the gap, but 
patients treated by providers without 
bulk replacement arrangements still 
must wait to receive donated medica-
tions and periodically must re-apply. 
• Eligibility restrictions: Numerous 
respondents across communities noted 
that individuals with incomes just 
above the thresholds of manufacturer 
assistance and other programs face par-
ticular barriers in accessing prescrip-
tion drugs. In addition, the require-
ments of most manufacturer programs 
limit their impact in communities 
where there are many undocumented 
immigrants who do not qualify, such as 
Orange County, Phoenix and Miami. 
Even for eligible individuals, the appli-
cation process for manufacturer assis-
tance programs remains complex, and 
some research suggests that the assis-
tance programs have difficulty meeting 
all of the medication needs for many 
patients.7
Furthermore, only about half of low-
income, uninsured people are aware of a 
safety net provider in their community.8
Given the considerable role safety net pro-
viders play in obtaining prescription drugs, 
there remain many low-income, uninsured 
people who may not have the same access 
to low-cost medications as those who, for 
instance, are treated at a community health 
center.
Policy Implications
While policy makers have focused on 
extending prescription drug coverage to 
Medicare beneficiaries, the prescription 
drug needs of nonelderly, low-income 
people without coverage are a growing 
problem. Despite federal efforts to expand 
primary care services for low-income, 
uninsured people over the past few years, 
there has been a lack of significant new 
resources at the federal or state levels spe-
cifically dedicated to prescription drugs for 
this population. At the same time, safety 
net providers report that funding has not 
kept pace with the increased number of 
patients they treat. 
To address the growing demand for 
prescription drugs, safety net providers 
have made acquiring free or reduced-cost 
medications an integral part of their daily 
operations. Even with an expanded set of 
strategies in place, providers and patients 
struggle with rising demand and costs, 
and prescription drug access remains a 
challenge across communities. With state 
budgets recovering from the economic 
downturn, more resources may become 
available for state prescription drug assis-
tance programs. Moreover, steps to expand 
and facilitate the use of strategies that lower 
drug costs for providers and patients—such 
as 340B and manufacturer assistance pro-
grams—could help reduce the strain on 
safety net providers and extend medica-
tions to more people.  
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Data Source
Approximately every two years, HSC 
researchers visit 12 nationally repre-
sentative metropolitan communities 
to track changes in local health care 
markets. The 12 communities are 
Boston; Cleveland; Greenville, S.C.; 
Indianapolis; Lansing, Mich.; Little 
Rock, Ark.; Miami; northern New 
Jersey; Orange County, Calif.; Phoenix; 
Seattle; and Syracuse, N.Y. In 2005, 
HSC researchers interviewed an array 
of market stakeholders about how 
low-income people obtain prescription 
drugs. These respondents included exec-
utives of approximately 40 safety net 
providers (the main safety net providers 
in each community, including hospitals, 
community health centers and free 
clinics), in addition to directors of local 
prescription drug programs, state policy 
makers, consumer advocates and others.
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